ANEW MEDICAL, INC. Introduces New Chief Financial Officer
ANEW MEDICAL, INC. Appoints New CFO
NEW YORK — ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA), a U.S.-based biotechnology firm focused on developing cell and gene-based therapies for aging and age-related conditions, has officially announced the appointment of Jeffrey LeBlanc as its new Chief Financial Officer (CFO). He succeeds interim CFO Edward Cong Wang, who previously was the CFO of Redwoods Acquisition Corp, the entity through which ANEW merged.
“We are thrilled to welcome Jeff LeBlanc to our team,” stated Dr. Joseph Sinkule, the Founder, Chairman, and CEO of ANEW. “Jeff brings over two decades of extensive experience in financial management, launching new initiatives, and achieving successful business exits. Earlier in his career, he held significant investment roles at Greenlight Capital and GE Capital, and he began his professional journey at McKinsey and Co. He is a graduate of MIT with a Bachelor of Science in Chemical Engineering and holds an MBA from Harvard Business School.”
Overview of ANEW MEDICAL, INC.
About the Company
ANEW MEDICAL, INC. (NASDAQ: WENA) is a cutting-edge biopharmaceutical enterprise that specializes in the development of patented, innovative technologies aimed at modifying diseases related to the brain and central nervous system (CNS), which are crucial for treating neurodegenerative and age-related ailments. The company has acquired exclusive worldwide rights to pioneering technologies and expertise for developing advanced protein, gene, and cell therapies aimed at addressing age-related diseases such as Alzheimer’s and Parkinson’s Disease, ALS, multiple sclerosis, and various rare neurodegenerative conditions. Currently, ANEW's portfolio includes its proprietary gene therapy platform utilizing DNA and RNA for therapeutic and diagnostic applications. In addition, the company focuses on clinical-stage programs that involve antibody biologics targeting cancer and autoimmune diseases and features a needle-free dry powder jet autoinjector called Nanoject for drug delivery.
Management Expertise
ANEW is guided by a skilled team of professionals and advisors with extensive experience in biopharmaceutical product development and commercialization. This strategic leadership positions the company favorably to navigate the complexities of the biotechnology sector.
Contact Information
For further details, please contact:
Eric Boyd
Investor Relations
Email: IR@anewmeds.com
Frequently Asked Questions
1. Who is the new Chief Financial Officer of ANEW MEDICAL, INC.?
The new Chief Financial Officer of ANEW MEDICAL, INC. is Jeffrey LeBlanc.
2. What experience does Jeffrey LeBlanc bring to ANEW MEDICAL, INC.?
Jeffrey LeBlanc brings over 20 years of experience in managing financial operations, launching new ventures, and achieving successful business exits, with investment roles at Greenlight Capital and GE Capital.
3. What areas does ANEW MEDICAL, INC. focus on in biotechnology?
ANEW MEDICAL, INC. focuses on developing cell and gene-based therapies for aging and age-related diseases, specifically targeting conditions like Alzheimer’s and Parkinson’s disease.
4. What unique technologies does ANEW MEDICAL, INC. develop?
The company develops patented disease-modifying technologies for the brain and central nervous system, along with gene therapy programs using DNA and RNA.
5>How can investors contact ANEW MEDICAL, INC.?
Investors can contact Eric Boyd in Investor Relations via email at IR@anewmeds.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/